Loratadine

FAA Research Institute contributes to global study proving mepolizumab's effectiveness in reducing severe asthma exacerbations Our team’s commitment to advancing asthma care through research is unwavering, showcasing how collaboration and innovation improve patient outcomes.” — Dr. Stephen Pollard LOUISVILLE, KY, UNITED STATES, August 13, 2025 / EINPresswire.com / -- Family Allergy & Asthma (FAA) is proud to announce that Dr. Stephen Pollard, Principal Investigator at the FAA Research Institute, has been published as a co-author in the prestigious Annals of Allergy, Asthma & Immunology. The study, titled “ Mepolizumab Real-World Effectiveness in Severe Asthma with an Eosinophilic Phenotype and Overlapping Severe Allergic Asthma,” represents a significant advancement in the understanding and treatment of severe asthma. This large-scale, real-world study highlights the effectiveness of mepolizumab, a biologic therapy targeting eosinophilic inflammation, in reducing asthma exacerbations in patients with overlapping allergic and eosinophilic phenotypes. The findings provide critical insights for clinicians managing complex asthma cases, where multiple biologic treatment options may be considered. A Team Effort in Research Excellence The success of this study is a testament to the dedication and expertise of the FAA Research Institute team. Research coordinators Becky Whitehead and Amber Noe played a pivotal role in patient recruitment, retention, and data management, ensuring the study’s success. While not listed as authors, their behind-the-scenes contributions were instrumental and reflect the high standards of FAA’s clinical research staff. “Our team’s commitment to advancing asthma care through research is unwavering,” said Dr. Stephen Pollard. “This study is a prime example of how collaboration and innovation can lead to meaningful improvements in patient outcomes.” Join the FAA Research Institute’s Mission Since 1991, the FAA Research Institute has been at the forefront of clinical research, contributing to the development of groundbreaking treatments like Zyrtec, Allegra, Claritin, Flonase, and Nasonex. Located at the Goss Avenue location in Louisville, KY, the institute boasts state-of-the-art technology and a computerized database of over 15,000 patients. The institute collaborates with leading national pharmaceutical and clinical research organizations, ensuring that all studies are closely monitored by the FDA and Institutional Review Boards to prioritize participant safety and rights. Why Participate in Clinical Research? Participants in FAA’s clinical trials benefit from: Personalized care with close monitoring of health conditions. Access to study-related office visits, physician exams, and medications. Reimbursement for time and travel. The opportunity to contribute to advancements in treatments for asthma, allergies, and other conditions. “Our research is fueled by a shared goal to enhance lives through evidence-based findings and innovations,” said Becky Whitehead, Director of Clinical Research. “By joining our studies, participants not only gain access to cutting-edge treatments but also play a vital role in shaping the future of care.” Current Research Opportunities The FAA Research Institute is currently recruiting participants for studies on asthma, food allergies, COPD, dermatitis, and more. To learn more about ongoing trials or to participate, contact the FAA Research Institute at 502.368.0732 or visit familyallergy.com. Advancing Asthma Care Through Cutting-Edge Research Family Allergy & Asthma’s participation in this peer-reviewed publication underscores its dedication to leading-edge research and evidence-based treatment. By contributing to the evolving landscape of biologic therapies for severe asthma, FAA continues to support clinicians and patients in making informed treatment decisions. About Family Allergy & Asthma Research Institute Family Allergy & Asthma is a leading provider of allergy and asthma care, offering comprehensive services to patients across Louisville, KY. With a strong focus on clinical research, FAA is committed to improving the lives of individuals with asthma and allergies through innovative treatments and personalized care. For more information about this study or Family Allergy & Asthma’s research initiatives, please contact Research Department Director Becky White at bwhite@familyallergy.com Becky Whitehead Family Allergy & Asthma +1 502-368-0732 bwhite@familyallergy.com Visit us on social media: LinkedIn Instagram Facebook YouTube X Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

“I’m excited to leverage my passion for building consumer-led, purpose-driven brands across the Consumer Health portfolio, which includes many brands that I know and love, like Claritin, Aspirin, and Midol,” Samantha Avivi said in this week's announcement. In yet another C-suite shift for Bayer’s consumer health business, the division’s North America segment has appointed a new chief marketing officer. Samantha Avivi is slated to take over the role from Jeff Jarrett, Bayer announced Tuesday. Jarrett had served as marketing chief for Bayer Consumer Health’s North America region since mid-2020—a year after he joined the pharma—and is planning to retire from the company at the end of May. In a LinkedIn post Tuesday, Jarrett called his departure “truly bittersweet,” as he cited the “incredible journey” of working at Bayer while noting that “after five years at Bayer, and nearly 55 years of life, I’m ready for the next chapter… whatever it may hold!” Jarrett also congratulated Avivi on taking the reins, writing, “I’m confident her breadth of experience across so many world-class agencies and companies will bring tremendous value to our brand-building strategy and capabilities moving forward.” Avivi joins Bayer fresh off a yearlong stint as chief marketing officer of Advance Auto Parts, which followed about three years spent as marketing chief of another auto parts company, Tenneco. Rounding out her nearly 30-year career in marketing are leadership roles at consumer goods giants Kimberly-Clark and Procter & Gamble, and at agencies including BBDO, Young & Rubicam (now part of VMLY&R) and DMB&B, prior to its acquisition by Publicis. In her new position, Avivi will spearhead North American marketing efforts for Bayer’s range of consumer brands. She’ll report to Dave Tomasi, president of Consumer Health, North America for Bayer. “I’m excited to leverage my passion for building consumer-led, purpose-driven brands across the Consumer Health portfolio, which includes many brands that I know and love, like Claritin, Aspirin, and Midol,” she said in the announcement. Avivi’s appointment is the latest in a spate of recent executive moves for Bayer’s consumer health department. Her new boss, Tomasi—also a Procter & Gamble alum—took on the president role just last summer, following three years as chief commercial officer for the North American consumer health segment. And earlier this year, Bayer announced a new head of the global consumer health business: Julio Triana, currently head of international commercial operations in Bayer’s pharma division, who’s set to take over the president title from Heiko Schipper on May 1. Those high-level switch-ups have taken place as Bayer continues to stave off calls for a separation of the consumer health business. During an investor day last month, CEO Bill Anderson said the company had considered selling off the division but has so far decided against it because of the sizable tax losses such a separation would bring and because the consumer health brands are still generating sold cash flow, among other reasons. This year, Bayer is expecting consumer health sales to grow between 3% and 6% while forecasting that pharma will stay flat or drop up to 4%.